Ultragenyx Pharmaceutical Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on February 21, 2019. The report addresses a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is an event-driven report and does not contain financial statements.
Material Changes and Events
On February 21, 2019, the company announced positive longer-term topline safety and efficacy data from the first, lowest dose cohort of an ongoing Phase 1/2 study. The study evaluates DTX401, an adeno-associated virus-based gene therapy designed for the treatment of glycogen storage disease type Ia.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) containing the full details of the clinical data. No specific financial guidance, management outlook, or new risk factors are detailed within the text of this 8-K form itself.
Investor Verification Checklist
- Review the full text of the press release filed as Exhibit 99.1 for detailed clinical trial results.
- Verify the specific safety and efficacy metrics reported for the DTX401 lowest dose cohort.
- Confirm the timeline for subsequent dose cohorts in the Phase 1/2 study.
- Check for any updated regulatory milestones associated with glycogen storage disease type Ia treatments.